Navidea Biopharmaceuticals, Inc. announced that it has entered into a Stock Purchase Agreement with two accredited investors pursuant to which the company agreed to issue a private placement a total of 11,000 shares of Series J convertible preferred stock at a price of $100 per share for the gross proceeds of $1,100,000 on May 22, 2023.The Company also agreed to provide the investors with certain registration rights related to the resale of the shares of the company's common stock, par value $0.001 per share issuable upon conversion of the Series J preferred stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0381 USD | +1.33% | +8.86% | -30.98% |
1st Jan change | Capi. | |
---|---|---|
-30.98% | 3.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NAVB Stock
- News Navidea Biopharmaceuticals, Inc.
- Navidea Biopharmaceuticals, Inc. announced that it expects to receive $1.1 million in funding